Ribozymes and the anti-gene therapy: How a catalytic RNA can be used to inhibit gene function

Gene

Volumn 237, Issue 2, 1999, Pages 303-310

  Muotri, Alysson Renato ^a   Da Veiga Pereira, Lygia ^a   Dos Reis Vasques, Luciana ^a   Menck, Carlos Frederico Martins ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Catalytic RNA; Gene inhibition; Ribozymes

Indexed keywords

RIBOZYME;

DNA SEQUENCE; DNA SYNTHESIS INHIBITION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE THERAPY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE;

ANIMALS; BASE SEQUENCE; GENE EXPRESSION REGULATION; HUMANS; RNA, CATALYTIC;

EID: 0032833304     PISSN: 03781119     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-1119(99)00334-0     Document Type: Review

References (93)

1. Anderson W.F. Human gene therapy. Nature. 392:1998;25-30.
2. Arndt G.M., Rank G.H. Colocalization of antisense RNAs and ribozymes with their target mRNAs. Genome. 40:1997;785-797.
3. Arts E.J., Wainberg M.A. HIV-1 reverse transcriptase and early events in reverse transcription. Adv. Virus Res. 46:1996;97-163.
4. Bauer G., Valdez P., Kearns K., Bahner I., Wen S.F., Zaia J.A., Kohn D.B. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34(+) cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood. 89:1997;2259-2267.
5. Beck J., Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidations signal in vitro and in cell extracts, but not in intact cells. Nucleic Acids Res. 23:1995;4954-4962.
6. Blobel G. Gene gating: a hypothesis. Proc. Natl. Acad. Sci. USA. 82:1995;8527-8529.
7. Breaker R.R., Joyce G.F. A DNA enzyme that cleaves RNA. Chem. Biol. 1:1994;223-229.
8. Butcher S.E., Burke J.M. Structure-mapping of the hairpin ribozyme. Magnesium-dependent folding and evidence for tertiary interactions within the ribozyme-substrate complex. J. Mol. Biol. 244:1994;52-63.
9. Cairns M.J., Hopkins T.M., Witherington C., Wang L., Sun I.Q. Target site selection for an RNA-cleaving catalytic DNA. Nat. Biotechnol. 17:1999;480-486.
10. Capecchi M.R. Target gene replacement. Sci. Am. 270:1994;52-59.
11. Cech T.R., Zaug A.J., Grabowski P.J. In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell. 27:1981;487-496.
12. Chambers C.A. TKO'ed: lox, stock and barrel. Bioessays. 16:1994;865-868.
13. Chan P.P., Glazer P.M. Triplex DNA: fundamentals, advances and potential applications for gene therapy. J. Mol. Med. 75:1997;267-282.
14. Chang M.Y., Won S.J., Liu H.S. A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell lines. J. Cancer Res. Clin. Oncol. 123:1997;91-99.
15. Chen C.J., Banerjea A.C., Harmion G.G., Haglund K., Schubert M. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potencial effectiveness against most presently sequenced HIV-1 isolates. Nucleic Acids Res. 20:1992;4581-4589.
16. Chen Z., Kamath P., Zhang S., Weil M.M., Shillitoe E.J. Effectiveness of three ribozymes for cleavage of an RNA transcript from human papillomavirus type 18. Cancer Gene Ther. 2:1995;263-271.
17. Cuenoud B., Szostak J.W. A DNA metalloenzyme with DNA ligase activity. Nature. 375:1995;611-614.
18. Dahm S.C., Uhlenbeck O.C. Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry. 30:1991;9464-9469.
19. Ding D., Lipshitz H.D. Localized RNAs and their functions. Bioessays. 15:1993;651-658.
20. Dorai T., Olsson C.A., Katz A.E., Buttyan P. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate. 32:1997;246-258.
21. Duan L., Zhu D., Ozaki I., Zhang H., Wei D.L., Pomerantz R.J. Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy. Gene Ther. 4:1997;533-543. published corrigendum appears in Gene Ther. 5 (1998) 570.
22. Earnshaw D.J., Gait M.J. Hairpin ribozyme cleavage catalyzed by aminoglycoside antibiotics and the polyamine spermine in the absence of metal ions. Nucleic Acids Res. 26:1998;5551-5561.
23. Ekland E.H., Bartel D.P. The secondary structure and sequence optimisation of an RNA ligase ribozyme. Nucleic Acids Res. 23:1995;3231-3238.
24. Fedor M.J., Uhlenbeck O.C. Kinetics of intermolecular cleavage by hammerhead ribozymes. Biochemistry. 31:1992;12042-12054.
25. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranted RNA in Caenorhabditis elegans. Nature. 391:1998;806-811.
26. Frank-Kamenetskii M.D., Mirkin S.M. Triplex DNA structures. Annu. Rev. Biochem. 64:1995;65-95.
27. Goodchild J. Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation. Nucleic Acids Res. 20:1992;4607-4612.
28. Guerrier T., Altman S. Catalytic activity of an RNA molecule prepared by transcription in vitro. Science. 223:1984;285-286.
29. Guo S., Kemphues K.J. Par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 81:1995;611-620.
30. Hampel A. The Hairpin ribozyme: discovery, two-dimensional model, and development for gene therapy. Progr. Nucleic Acid Res. Mol. Biol. 58:1998;1-39.
31. Heidenreich O., Benseler F., Fahrenholz A., Eckstein F. High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine necleosides and phosphorothioates. J. Biol. Chem. 269:1994;2131-2138.
32. Hertel K.J., Herschlag D., Uhlenbeck O.C. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. Biochemistry. 33:1994;3374-3385.
33. 2+ binding affinities to the hammerhead ribozyme and correlation with cleavage activity. Biochemistry. 37:1998;18094-18101.
34. Hsieh S.Y., Taylor J. Delta virus as a vector for the delivery of biologically-active RNAs: possibly a ribozyme specific for chronic hepatitis B virus infection. Adv. Exp. Med. Biol. 312:1992;125-128.
35. Ishizaka M., Ohshima Y., Tani T. Isolation of active ribozymes from an RNA pool of random sequences using an anchored substrate RNA. Biochem. Biophys. Res. Commun. 214:1995;403-409.
36. Jaeger J.A., Turner D.H., Zuker M. Improved predictions of secondary structures for RNA. Proc. Natl. Acad. Sci. USA. 86:1989;7706-7710.
37. Jaeger L. The new world of ribozymes. Curr. Opin. Struct. Biol. 7:1997;324-335.
38. Kiehntopf M., Esquivel E.L., Brach M.A., Herrmann R. Ribozymes: biology, biochemistry, and implications for clinical medicine. J. Mol. Med. 73:1995;65-71.
39. Koizumi M., Hayase Y., Iwai S., Kamiya H., Inoue H., Ohtsuka E. Design of RNA enzymes distinguishing a single base mutation in RNA. Nucleic Acids Res. 17:1989;7059-7071.
40. Koizumi M., Kamiya H., Ohtsuka E. Ribozymes designed to inhibit transformation of NIH/3T3 cells by the activated c-Ha-ras gene. Gene. 117:1992;179-184.
41. Larsson S., Hotchkiss G., Su J., Kebede T., Andäng M., Nyholm T., Johansson B., Sönnerborg A., Vahlne A., Britton S., Ährlund-Richter L. A novel ribozyme target site located in the HIV-1 nef open reading frame. Virology. 219:1996;161-169.
42. Lawrence J.B., Singer R.H. Intracellular localization of messenger RNAs for cytoskeletal proteins. Cell. 45:1986;407-415.
43. Lehninger A.L. Principles of Biochemistry. 1982;Worth Publishers, New York, NY.
44. Li A., Gervaix A., Kang D., Law P., Spector S.A., Ho A.D., Wong-Staal F. Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. Gene Ther. 5:1998;233-239.
45. Li Y., Breaker R.R. Deoxyribozymes: new players in the ancient game of biocatalysis. Curr. Opin. Struct. Biol. 9:1999;315-323.
46. Lieber A., He C.Y., Polyak S.J., Gretch D.R., Barr D., Kay M.A. Elimination of hepatitis C virus RNA in infected human hepatocytes by adenovirus-mediated expression of ribozymes. J. Virol. 70:1996;8782-8791.
47. Lo K.M., Biasolo M.A., Dhni G., Palu G., Haseltine W.A. Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology. 190:1992;176-183.
48. Lu D., Chatterjel S., Bran D., Wong K.K. Jr. Ribozyme-mediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Ther. 1:1994;267-277.
49. Maeda A., Mizutani T., Hayashi M., Watanabe T., Namioka S. Inhibition of viral multiplication by hammerhead ribozymes targeted against the polymerase gene of mouse hepatitis virus. J. Vet. Med. Sci. 56:1994;939-945.
50. Maeda A., Hayashi M., Mizutani T., Ishida K., Watanabe T., Namioka S. Inhibition of viral multiplication in cells chronically infected with mouse hepatitis virus by antisense RNA against the polymerase gene. J. Vet. Med. Sci. 57:1995;563-565.
51. Margolis H.S., Alter M.J., Hadler S.C. Hepatitis B: evolving epidemiology and implications for control. Semin. Liver Dis. 11:1991;84-92.
52. Mizutani T., Hayashi M., Maeda A., Sasaki N., Yamashita T., Kasai N., Namioka S. Inhibition of mouse hepatitis virus multiplication by antisense oligonucleotide, antisense RNA, sense RNA and ribozyme. Adv. Exp. Med. Biol. 342:1993;129-135.
53. Montgomery R.A., Dietz H.C. Inhibition of fibrilin-1 expression using U1 snRNA as a vehicle for the presentation of antisense targeting sequence. Hum. Mol. Genet. 6:1997;519-525.
54. Netter H.J., Hsieh S.Y., Lazinski D., Taylor J. Modified HDV as a vector for the delivery of biologically-active RNAs. Prog. Clin. Biol. Res. 282:1993;373-376.
55. Ojwang J., Hampel A., Looney D., Wong-Staal F., Rapport J. Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc. Natl. Acad. Sci. USA. 89:1992;10802-10806.
56. Paolella G., Sproat B., Lamond A.I. Nuclease resistant ribozymes with high catalytic activity. EMBO J. 11:1992;1913-1919.
57. Persidis A. Ribozyme therapeutics. Nature Biotechnol. 15:1997;921-922.
58. Pestka S., Daugherty B.L., Jung V., Hotta K., Pestka R.K. Anti-mRNA: specific inhibition of translation of single mRNA molecules. Proc. Natl. Acad. Sci. USA. 81:1984;7525-7528.
59. Pieken W.W.A., Olsen D.B., Banseler F., Aurup H., Eckstein F. Kinetic characterization of ribonuclease resistan 2′-modified hammerhead ribozymes. Science. 253:1991;314-317.
60. Radhakrishnan I., Patel D. DNA Triplex: Solution Structures, Hydration Sites, Energies, Interactions and Functions. Biochemistry. 33:1994;11405-11416.
61. Ramezani A., Ding S.F., Joshi S. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Gene Ther. 4:1997;861-867.
62. Riddell S.R., Elliot M., Lewinsohn D.A., Gilbert M.J., Wilson L., Manley S.A., Lupton S.D., Overell R.W., Reynolds T.C., Corey L., Greenberg P.D. T-Cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2:1996;216-223.
63. Sakamoto N., Wu C.H., Wu G.Y. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J. Clin. Invest. 98:1996;2720-2728.
64. Samarsky D.A., Ferbeyre G., Bertrand E., Singer R.H., Cedergren R., Fournier M.J. A small nucleolar RNA:ribozyme hybrid cleaves a nucleolar RNA target in vivo with near-perfect efficiency. Proc. Natl. Acad. Sci. USA. 96:1999;6609-6614.
65. Sauer B., Henderson N. Site-specific recombination in mammalian cells by the Cre recombinase of bacteriophage P1. Proc. Natl. Acad. Sci. USA. 85:1988;5166-5170.
66. Scanlon K., Jiao L., Funato T., Wang W., Tone T., Rossi J.J., Kashani S.M. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. USA. 88:1991;10591-10595.
67. Shimayama T., Nishikawa F., Nishikawa S., Kazunasi T. Nuclease resistant chimeric ribozymes containing deoxyribonucleotide and phosphorothioate linkages. Nucleic Acids Res. 21:1993;2605-2611.
68. Sioud M., Natuig J.B., Forre O. Preformed ribozyme destroys tumor necrosis factor in RNA in human cells. J. Mol. Biol. 223:1992;831-835.
69. Snyder D.S., Wu Y., Wang J.L., Rossi J.J., Swiderski P., Kaplan B.E., Forman S.J. Ribozyme-mediated inhibition of bcl-abl gene expression in a Philadelphia chromosome-positive cell line. Blood. 82:1993;600-605.
70. Sperelakis N. Cell Physiology Source Book. 1995;Academic Press, New York.
71. Stein C.A., Tonkinson J.L., Zhang L.M., Yakubov L., Gervasoni J., Taub R., Rotemberg S.A. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry. 32:1993;4855-4861.
72. Stein C.A. Does antisense exist? Nat. Med. 1:1995;1119-1121.
73. Sullenger B.A., Cech T.R. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science. 262:1993;1566-1568.
74. Sun L.Q., Warrilow D., Wang L., Witherington C., Macpherson J., Symonds G. Ribozyme-mediated suppression of MoMuLV and HIV-1 replication in permissive cell lines. Proc. Natl. Acad. Sci. USA. 91:1994;9715-9719.
75. Symons R.H. Small catalytic RNAs. Annu. Ver. Biochem. 61:1992;641-671.
76. Tabara H., Grishok A., Mello C.C. RNAi in C.elegans: soaking in the genome sequence. Science. 282:1998;430-431.
77. Tang X.B., Hobom G., Luo D. Ribozyme mediated destruction of influenza A virus in vitro and in vivo. J. Med. Virol. 42:1994;385-395.
78. Taylor N.R., Kaplan B.A., Swiderski P., Li H., Rossi J.J. Chimeric DNA-RNA hammerhead ribozymes have enhanced in vivo catalytic efficiency and increased stability in vivo. Nucleic Acids Res. 20:1992;4559-4565.
79. Twomey C.M., Gibson I. The intracellular distribution of fluorescently labeled ribozyme in the 32Bb3a2 murine cell line. Molecular and Cellular Biology of Gene Therapy. Keystone Symposia. Snowbird, UT. 1997;71.
80. Uhlenbeck O.C. A small catalytic oligoribonucleotide. Nature. 328:1987;596-600.
81. Uhlmann E., Peymann A. Antisense oligonucleotides: a new therapeutic principle. Chem. Rev. 90:1990;543-584.
82. Verma I.M., Somia N. Gene therapy-promises, problems and prospects. Nature. 389:1997;239-242.
83. Wagner R.W. Toward a broad-based antisense technology. Antisense Res. Dev. 5:1995;113-114.
84. Wang L., Ruffner D.E. Novel configurations of the hammerhead ribozyme: Increased activity and reduced magnesium ion requirement. Biochem. Biophys. Res. Commun. 250:1998;711-719.
85. Welch P.J., Tritz R., Yei S., Leavitt M., Yu M., Barber J. A potential therapeutic applications of hairpin ribozymes: In vitro and in vivo studies of gene therapy for hepatitis C virus infection. Gene Ther. 3:1996;994-1001.
86. Welch P.J., Tritz R., Yei S., Barber J., Yu M. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther. 4:1997;736-743.
87. Wong-Staal F., Poeschla E.M., Looney D.J. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum. Gene Ther. 9:1998;2407-2425.
88. Yamada O., Yu M., Yee J.K., Kraus G., Looney D., Wong-Staal F. Intracellular immunization of human T-cells with a hairpin ribozyme against human immunodeficiency virus type 1. Gene Ther. 1:1994;38-45.
89. Yamada O., Kraus G., Luznik L., Yu M., Wong-Staal F. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J. Virol. 70:1996;1596-1601.
90. Yang J.H., Usman N., Chartrand P., Cedergreen R. Minimum ribonucleotide requirement for catalysis by the RNA hammerhead domain. Biochemistry. 31:1992;5005-5009.
91. Yoffe B., Noonnan C.A. Hepatitis B virus: new and evolving issues. Digest Dis. Sci. 37:1992;1-9.
92. Young K.J., Gill F., Grasby J.A. Metal ions play a passive role in the hairpin ribozyme catalyzed reaction. Nucleic Acids Res. 25:1997;3760-3766.
93. Yu M., Leavitt M.C., Maruyama M., Yamada O., Young D., Ho A.D., Wong-Staal F. Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against HIV-1. Proc. Natl. Acad. Sci. USA. 92:1995;699-703.